Most Read Articles
Elvira Manzano, 13 Apr 2020
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Pearl Toh, 23 Apr 2020
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Roshini Claire Anthony, 17 Jul 2020

Icosapent ethyl may reduce the risk of cardiovascular (CV) events in patients with diabetes mellitus (DM) taking statins, according to findings of REDUCE-IT DIABETES presented at ADA 2020.

Elaine Soliven, 12 Apr 2019
The use of catheter ablation as first-line treatment reduces the number of premature ventricular complexes (PVCs) in a paediatric population, according to a study presented at EHRA 2019.

Psoriasis drug may help fight coronary plaques

10 Feb 2019

Biologic therapies for severe psoriasis appear to help reduce noncalcified coronary plaques and improve plaque morphology, a recent study has shown.

Researchers conducted a prospective observational study including 121 psoriasis patients, of whom 89 received biologic treatments (mean age 49.1±12.2 years; 56 percent male) and 32 (mean age 51.2±12.0 years; 63 percent male) were treated with other agents. Participants tended to have low cardiovascular risk (median Framingham score, 3) with moderate-to-severe skin disease (median Psoriasis Area and Severity Index [PASI], 8.6).

After a year of follow-up, patients who were treated with biologic agents showed significant improvements in the PASI score (64-percent improvement, p<0.001), as well as a significant reduction in high-sensitivity C-reactive protein levels (p<0.001). No such changes were observed in the comparison group.

Moreover, a 5-percent decrease in total coronary plaque burden was observed in participants on biologic therapy (p=0.009), an effect primarily driven by a drop in the noncalcified plaque burden (p=0.005). No improvements in fibrous burden (p=0.71) were reported, though fibro-fatty (p=0.004) and necrotic (p=0.03) burdens decreased.

In comparison, those receiving nonbiologic interventions showed no significant 1-year change in total plaque burden (p=0.22), noncalcified plaque burden (p=0.17) and fibrous burden (p=0.22). There was also an increase in fibro-fatty burden (p=0.004).

Intergroup comparisons showed that the 1-year reduction in noncalcified plaque was significantly greater in patients treated with biologic agents (p=0.03) even after adjustments for cardiovascular risk factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 13 Apr 2020
A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.
Pearl Toh, 23 Apr 2020
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
Roshini Claire Anthony, 17 Jul 2020

Icosapent ethyl may reduce the risk of cardiovascular (CV) events in patients with diabetes mellitus (DM) taking statins, according to findings of REDUCE-IT DIABETES presented at ADA 2020.

Elaine Soliven, 12 Apr 2019
The use of catheter ablation as first-line treatment reduces the number of premature ventricular complexes (PVCs) in a paediatric population, according to a study presented at EHRA 2019.